Localized pustular psoriasis is a term that refers to a limited area of small pus-filled blisters on your skin, typically on your hands or feet. It is distinct from generalized pustular psoriasis (GPP ...

WAILEA, Hawaii — Treating localized, mild to moderate psoriasis is incredibly important to patients and there are many topical options to utilize in this endeavor, according to a speaker at the Maui ...

Crops of sterile pustules appear in groups on the palmoplantar surfaces. The surrounding skin is thickened, scaly, and erythematous. The right, dominant hand is more affected than the left. There are ...

You’ve probably heard of psoriasis—the chronic inflammatory condition that can cause itchy, scaly patches on your skin. Less well-known is a rare form of the disease called pustular psoriasis, which ...

Edward W. Cowen, MD, MHSc, senior clinician and acting branch chief, Dermatology Branch, National Institutes of Health, discusses treatment considerations for patients with different types of pustular ...

Recent studies imply that acute generalized exanthematous pustulosis (AGEP) is a well orchestrated, cell-mediated, immunologic reaction with afferent and efferent pathways. [2] T lymphocytes are ...

This article was medically reviewed by Caroline Chang, MD, a board-certified dermatologist and member of the Prevention Medical Review Board, on August 8, 2019. We all get rashes from time to time, ...

Psoriasis can involve any area of the skin. The most common areas are those that are prone to significant trauma from rubbing or scratching. These areas include the elbows, knees and scalp. However, ...

Acute generalized exanthematous pustulosis (AGEP) is a rare adverse skin reaction usually caused by medication or acute infection. As numerous diseases may present with pustular eruptions, it is ...

Psoriasis is a chronic skin disease where red, scaly, itchy patches break out all over your body. It’s an autoimmune disease in which your immune system goes haywire and triggers inflammation of your ...

BRACKNELL, England--(BUSINESS WIRE)--Boehringer Ingelheim announced today the publication in the New England Journal of Medicine of new data from the pivotal Phase II Effisayil TM 1 trial, which ...